Medicine

Permanent URI for this communityhttp://repository.kln.ac.lk/handle/123456789/12

This repository contains the published and unpublished research of the Faculty of Medicine by the staff members of the faculty

Browse

Has files: YesSubject: search.filters.subject.Hepatitis B

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy
    (Springer,New York, 2022) Kumar, M.; Abbas, Z.; Azami, M.; Belopolskaya, M.; Dokmeci, A.K.; Ghazinyan, H.; Jia, J.; Jindal, A.; Lee, H.C.; Lei, W.; Lim, S.G.; Liu, C.J.; Li, Q.; Mahtab, M.A.; Muljono, D.H.; Niriella, M.A.; Omata, M.; Payawal, D.A.; Sarin, S.K.; Ségéral, O.; Tanwandee, T.; Trehanpati, N.; Visvanathan, K.; Yang, J.M.; Yuen, M.F.; Zheng, Y.; Zhou, Y.H.
    Hepatitis B virus (HBV) infection still remains a major public health issue in the Asia-Pacific region. Most of the burden of HBV-related disease results from infections acquired in infancy through perinatal or early childhood exposure to HBV in Asia-Pacific. Hepatitis B during pregnancy presents unique management issues for both the mother and fetus. These APASL guidelines provide a comprehensive review and recommendations based on available evidence in the literature, for the management of females with HBV infection through every stage of pregnancy and postpartum. These also address the concerns, management challenges, and required follow-up of children born to hepatitis B-positive mothers.
  • No Thumbnail Available
    Item
    Study on immunity against Hepatitis B in children after vaccination during infancy
    (Sri lanka Medical Association, 2015) Perera, K.P.J.; Hapugoda, M.; Fernando, K.M.D.; Dimal, D.A.
    INTRODUCTION AND OBJECTIVES: Hepatitis B vaccine is given in Sri Lanka to all infants at 2, 4,6 months. As a low prevalent country the risk of acquiring Hepatitis B is more likely during adolescence and later. It is important to know whether immunity produced by vaccination during infancy last up to this stage, or a booster dose is needed to augment the immune response. METHOD: With informed written consent and assent from children, 150 ten year old school children with evidence of Hepatitis B vaccination during infancy, were tested for Hepatitis B antibody status using ELISA. Children who had an antibody titre less lOmlU/mL were offered a free booster dose. Antibody levels were retested one month after the booster. RESULTS: 128 (67%) had an antibody titre above 10m ID/ml. All children with a titre <10mlU/ml, accepted the booster dose. All children who received the booster had an antibody response above 10mlU/l, while (72%) had a titre >100mlU/l. CONCLUSION: Vaccination against Hepatitis B during infancy appear to produce protective level of antibodies at ten years of age. Even the children with antibody titres below protective level produced a sharp rise in titres with a booster dose. As this response could be expected with a natural infection, booster dose to augment the immune response produced by vaccination during infancy is not needed.
  • Thumbnail Image
    Item
    Prevalence of hepatitis B and hepatitis C infections and their relationship to injectable drug use in a cohort of Sri Lankan prison inmates
    (Sri Lanka Medical Association, 2015) Niriella, M.A.; Hapangama, A.; Luke, H.P.D.P.; Pathmeswaran, A.; Kuruppuarachchi, K.A.L.A.; de Silva, H.J.
    INTRODUCTION: Prisoners are considered to be at high risk for Hepatitis B (HBV) and Hepatitis C (HCV) virus infections. This is attributed to intravenous drug use and high-risk sexual behaviour. There are no published studies on HBV and HCV among prison inmates or injecting drug users in Sri Lanka. OBJECTIVES: To determine prevalence of HBV and HCV infections, and their relationship to injectable drug use among Sri Lankan prisoners. METHODS: We investigated 393 (median age 42 years (range 16 to 93); 82% males) randomly selected inmates of Mahara and Welikada prisons. RESULTS: Though 167 (42.5%) admitted drug abuse, only 17 (4.3%) had ever used intravenous drugs. Twelve (70.6%) of them reported sharing needles. One inmate was positive for HBsAg but was negative for HBV-DNA. Twenty seven (6.9%) were positive for anti-HCV antibodies, of whom only 2 (0.5%) were positive for HCV-RNA. None of the injecting drug users were positive for HBV-DNA or HCV-RNA. CONCLUSIONS: The prevalence of HBV and HCV infections as well as injecting drug use was very low among this cohort of Sri Lankan prisoninmates
All items in this Institutional Repository are protected by copyright, with all rights reserved, unless otherwise indicated. No item in the repository may be reproduced for commercial or resale purposes.